Ken Griffin, founder of Citadel, bought 2.7 million more AbbVie (ABBV) shares in Q2, a 546% increase from the prior quarter, and added 6.7 million Abbott Laboratories (ABT) shares, up 349%; Eli Lilly (LLY) was also boosted by 291%. The author sees these moves as defensive shifts into healthcare and a search for high-yield dividend stocks amid possibly volatile markets. AbbVie has raised its dividend for 54 straight years when Abbott's years are included, and its 2.65% yield is its lowest since 2018 because the stock is up about 25% year to date. In Q2, AbbVie's adjusted earnings rose 23% and net revenue rose 10%, and 75% of analysts following the stock rate it a buy.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Ken Griffindividendshedge funds
Open a keyword to see other news on the same topic.
Related news
- Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson's third-quarter revenue rose 6% to $25.9 billion and adjusted EPS of $2.59 fell 7.5% year over year, both topping most analyst estimates, and the company raised its full-year 2026 operational sales growth guidance to 6.4% to 6.8%. However, MedTech revenue rose only 2.5% to $8.6 billion, short of the consensus of just over $8.7 billion, and the stock fell nearly 6% after the release; CFO Joe Wolk called the division's results 'disappointing,' and the company floated a spinoff of its DePuy Synthes orthopedics business sometime in 2027. The article notes MedTech accounts for about one-third of sales and under 20% of adjusted net income, while oncology grew more than 16% to $7.6 billion in the quarter, with J&J targeting at least $50 billion in oncology sales by 2030. It also highlights a forward dividend yield of about 2% backed by a 64-year dividend growth streak as a reason the stock may be easier to hold through volatility.
- Dr. Phil lists his lavish Beverly Hills estate for a whopping $67.5 million
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
- How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?
Medtronic has raised its quarterly dividend for 49 consecutive years, one year short of Dividend King status, which requires 50 years. At an annualized dividend of $2.88 per share, roughly 348 shares, costing about $32,792, would generate $1,002.24 in annual dividend income, a yield of around 3%. Recent dividend increases have been modest, at 1.4% this year and an average of 2% over three years. The spinoff of MiniMed, its lower-margin diabetes business, completed via an exchange offer this week, lets Medtronic focus on its higher-margin cardiovascular, neuroscience and surgical businesses. Analysts estimate earnings growth of 8.1% and 7.1% for the fiscal years ending January 2027 and January 2028, and with a 48% forward payout ratio, that could support larger dividend increases.
- Forget High - Yield Traps : AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The article argues AbbVie (ABBV) is not a high-yield trap, since its free cash flow comfortably covers its $1.73-per-share quarterly dividend and most of its $70.8 billion debt is fixed-rate. The company has raised its dividend for 54 consecutive years, qualifying it as a Dividend King. Skyrizi and Rinvoq together brought in over $7.5 billion in Q2 2026, more than the $6.1 billion paid in dividends that quarter, and AbbVie has about 90 clinical-development programs, roughly 60 of them in mid- or late-stage studies. Its 2.5% yield is lower than before mainly because the share price has risen sharply, and the article notes that pipeline setbacks remain a risk.
- Forget High - Yield Traps : AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The article argues AbbVie is not a high-yield trap, because its free cash flow is sufficient to cover its quarterly dividend of $1.73 per share, and most of its $70.8 billion debt is in fixed-rate notes. AbbVie has raised its dividend for 54 consecutive years, qualifying it as a Dividend King, a group of stocks that have raised dividends for at least 50 years. Skyrizi and Rinvoq together brought in over $7.5 billion in the second quarter of 2026, more than the $6.1 billion paid in dividends that quarter, and the company has about 90 programs in development, around 60 of them in mid- or late-stage studies. The dividend yield of 2.5% is lower than before because the share price has risen faster than dividends, and the article notes that pipeline setbacks remain a risk.
Related markets
Latest news
- JPMorgan's JPM Coin, representing dollar deposits, is coming to Ethereum: Bloomberg
JPMorgan will make JPM Coin, a token representing its dollar deposits, available to institutional clients on Ethereum, according to Bloomberg. The bank says Ethereum's liquidity makes it attractive to crypto companies seeking blockchain payments and to financial firms settling trades or backing tokenized assets. The move extends JPMorgan's blockchain work beyond Base and its private Kinexys network, which processes more than $7 billion daily. The bank did not say when the token will go live on Ethereum. Meanwhile, JPMorgan is among US banks planning a shared tokenized deposit network, but it was not on Swift's list of 17 banks preparing live transactions on its blockchain ledger in July.
- Cerrado Gold Reports 21% Year-Over-Year Increase in Q3 2026 Production Results at Minera Don Nicolas
Cerrado Gold reported Q3 2026 production of 16,685 GEO at the Minera Don Nicolas (MDN) mine in Santa Cruz Province, Argentina, up 21% from 13,832 GEO in Q3 2025. Year-to-date output reached 44,942 GEO, up 23% from 36,432 GEO in the comparable 2025 period. Heap leach output held steady at 9,649 GEO, while CIL output rose to 7,036 GEO as higher-grade Calandrias material, generally above 2.5 g/t gold, was routed to the Martinetas mill. Laboratory tests on selected material showed gold recoveries of up to 95%, versus about 60% expected from heap leaching, and the company now expects full-year 2026 production at the upper end of its 50,000 to 60,000 GEO guidance while targeting a new PEA by late Q1 2027.
- Is Visa Stock Still a Buy After Gaining 14% This Year?
Visa shares hit an all-time high of $401, up about 12% over the past two weeks from $359 at the end of September and up 14% year to date. Key catalysts include approval from the People's Bank of China to set up a bankcard clearing institution in China and the move of Visa Direct's stablecoin to commercial deployment on Oct. 15. Baird and BMO Capital both raised their price targets. Visa reports fiscal fourth-quarter earnings on Oct. 27 and has raised its dividend every year since 2009, last year by 14% to $0.67 per share. The author still considers the stock a buy ahead of earnings, citing a forward P/E of 24.
- Five things to watch in markets in the week ahead
Markets start the week with AI stocks under pressure after hotter-than-expected September inflation raised expectations of higher US rates and fed worries about debt-funded AI spending. Last week the Philadelphia semiconductor index fell 11.41% and the Nasdaq Composite lost 4.48%, with CoreWeave shedding about a quarter of its value and Oracle down 9.31%. Earnings are in focus, with SpaceX and Netflix reporting on Tuesday and Meta and Tesla on Wednesday after the close. Netflix reportedly plans to cut around 6% of its workforce, roughly 1,000 roles, its biggest reduction since 2022. SpaceX has also agreed to buy spectrum licenses from Grain Management for about $8 billion, a move into the wireless market.
- eMemory/PUFsecurity Showcases OCP S.A.F.E.-Approved PUFrt at OCP Global Summit, Strengthening AI Data Center Security with Caliptra
PUFsecurity, a subsidiary of eMemory Technology, was featured at Microsoft's Caliptra Workshop on Oct. 12, the opening day of the 2026 OCP Global Summit, which drew nearly 400 attendees. Its PUFrt received OCP S.A.F.E. Scope 3 approval after an independent assessment of its resistance to physical attacks such as fault injection and side-channel attacks, and is now listed on the OCP Marketplace. PUFrt provides the physical security foundation for Caliptra, an open-source hardware Root-of-Trust architecture, from key generation to chip mass-production testing. It has already been integrated into Caliptra products from ASPEED and security systems from several memory makers and networking chip vendors. The company says the milestone advances hardware security for cloud and AI infrastructure.
- Crypto vault deposits top $10 billion as lending risks draw regulatory scrutiny
Deposits into crypto lending vaults have risen from $4 billion at the start of last year to more than $10 billion, according to the Financial Times. Each vault is run by a 'curator' who selects lending strategies through smart contracts on DeFi platforms, sets risk limits and collects fees, with typical returns of 3% to 10% and riskier strategies reaching 20% or more. Risks include illiquid or hard-to-sell collateral, automatic liquidations, hacks and coding errors, while investors may focus on headline yields. Fintechs, digital asset treasury firms and hedge funds are among the main depositors, and Bitcoin lender Two Prime launched a vault on Pareto targeting 1.5% to 2% yields, with a minimum deposit of 5 WBTC and about $10 million of its own capital absorbing initial losses. U.S. and European regulators are examining whether existing rules should apply, and the SEC has questioned vaults that hold securities.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.